Gheuens Sarah — SEC insider filings
SEC reporting owner CIK 1881190. 34 insider filings on record with FilingPulse; latest filed 2026-10-28.
Transaction summary — filings shown
Covers all 34 filings on record, filed 2021-12-07 to 2026-10-28. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 27 legs across 20 filings — 94,857 shares, $3,219,596 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 89.
- Largest priced transaction: sale of 30,000 shares @ $30.48 ($914,400) in AGIOS PHARMACEUTICALS, INC., filed 2026-08-06.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | Chief Medical Officer | 30 | — | 27 legs · 94,857 sh · $3,219,596 | 85 |
| Viridian Therapeutics, Inc.\DE (VRDN) | Director | 4 | — | — | 4 |
Insider filings — Gheuens Sarah
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-28 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Option exercise (M): 7,866 @ $25.01 · Sale (S): 7,866 @ $37.69 · Option exercise (M): 7,866 (derivative) @ $0 | EDGAR |
| 2026-10-23 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Option exercise (M): 1,489 @ $25.01 · Sale (S): 1,489 @ $37.53 · Option exercise (M): 500 @ $25.01 · Sale (S): 500 @ $37.52 · Option exercise (M): 1,489 (derivative) @ $0 · Option exercise (M): 500 (derivative) @ $0 | EDGAR |
| 2026-08-06 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Sale (S): 30,000 @ $30.48 | EDGAR |
| 2026-07-02 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Option exercise (M): 8,375 @ $0 · Sale (S): 4,007 @ $37.56 · Option exercise (M): 8,375 (derivative) @ $0 | EDGAR |
| 2026-07-02 | 4 | Viridian Therapeutics, Inc.\DE (VRDN) | Grant/award (A): 32,341 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Option exercise (M): 3,000 (derivative) @ $0 · Grant/award (A): 3,000 (derivative) @ $0 | EDGAR |
| 2026-04-06 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Option exercise (M): 8,500 @ $0 · Sale (S): 2,940 @ $34.71 · Option exercise (M): 8,500 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Option exercise (M): 4,000 @ $0 · Sale (S): 1,187 @ $28.96 · Option exercise (M): 5,666 @ $0 · Sale (S): 1,681 @ $28.96 · Option exercise (M): 4,000 @ $0 · Sale (S): 1,187 @ $28.96 · +6 more | EDGAR |
| 2026-01-02 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Option exercise (M): 6,000 @ $0 · Sale (S): 2,932 @ $27.09 · Option exercise (M): 6,000 (derivative) @ $0 | EDGAR |
| 2025-11-13 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Option exercise (M): 2,454 @ $25.01 · Sale (S): 2,454 @ $43.78 · Option exercise (M): 2,454 (derivative) @ $0 | EDGAR |
| 2025-11-03 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Option exercise (M): 200 @ $25.01 · Sale (S): 200 @ $43.81 · Option exercise (M): 200 (derivative) @ $0 | EDGAR |
| 2025-10-29 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Option exercise (M): 3,302 @ $25.01 · Sale (S): 3,302 @ $43.92 · Option exercise (M): 3,302 (derivative) @ $0 | EDGAR |
| 2025-07-11 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Option exercise (M): 11,914 @ $25.01 · Sale (S): 11,067 @ $37.93 · Sale (S): 847 @ $38.76 · Option exercise (M): 11,914 (derivative) @ $0 | EDGAR |
| 2025-07-03 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Option exercise (M): 8,374 @ $0 · Sale (S): 4,091 @ $34.17 · Option exercise (M): 8,374 (derivative) @ $0 | EDGAR |
| 2025-07-02 | 4 | Viridian Therapeutics, Inc.\DE (VRDN) | Grant/award (A): 21,000 (derivative) @ $0 | EDGAR |
| 2025-06-26 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Option exercise (M): 6,000 @ $0 · Sale (S): 2,909 @ $33.54 · Option exercise (M): 6,000 (derivative) @ $0 | EDGAR |
| 2025-03-04 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Option exercise (M): 3,833 @ $0 · Sale (S): 1,137 @ $35.54 · Option exercise (M): 4,000 @ $0 · Sale (S): 1,187 @ $35.54 · Option exercise (M): 5,667 @ $0 · Sale (S): 1,681 @ $35.54 · +5 more | EDGAR |
| 2024-07-03 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Option exercise (M): 8,375 @ $0 · Sale (S): 3,705 @ $43.85 · Option exercise (M): 8,375 (derivative) @ $0 | EDGAR |
| 2024-06-28 | 4 | Viridian Therapeutics, Inc.\DE (VRDN) | Grant/award (A): 21,000 (derivative) @ $0 | EDGAR |
| 2024-03-05 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Option exercise (M): 3,834 @ $0 · Sale (S): 1,293 @ $32.57 · Option exercise (M): 4,000 @ $0 · Sale (S): 1,349 @ $32.57 · Grant/award (A): 17,000 (derivative) @ $0 · Grant/award (A): 60,000 (derivative) @ $0 · +2 more | EDGAR |
| 2024-02-14 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Option exercise (M): 2,162 @ $0 · Sale (S): 642 @ $25.14 · Option exercise (M): 2,162 (derivative) @ $0 | EDGAR |
| 2024-01-24 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Option exercise (M): 5,750 @ $0 · Sale (S): 1,708 @ $21.64 · Option exercise (M): 5,750 (derivative) @ $0 | EDGAR |
| 2024-01-09 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Option exercise (M): 5,000 @ $0 · Sale (S): 1,789 @ $22.99 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2023-09-25 | 4 | Viridian Therapeutics, Inc.\DE (VRDN) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2023-07-06 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Grant/award (A): 25,124 (derivative) @ $0 | EDGAR |
| 2023-06-30 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Option exercise (M): 5,750 @ $0 · Sale (S): 1,707 @ $28.36 · Option exercise (M): 5,750 (derivative) @ $0 | EDGAR |
| 2023-03-03 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Option exercise (M): 3,833 @ $0 · Tax withholding (F): 1,134 @ $25.02 · Grant/award (A): 12,000 (derivative) @ $0 · Grant/award (A): 44,000 (derivative) @ $0 · Option exercise (M): 3,833 (derivative) @ $0 | EDGAR |
| 2023-02-14 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Option exercise (M): 2,162 @ $0 · Tax withholding (F): 758 @ $28.44 · Option exercise (M): 2,162 (derivative) @ $0 | EDGAR |
| 2022-12-28 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Option exercise (M): 9,375 @ $0 · Tax withholding (F): 2,783 @ $28.48 · Option exercise (M): 9,375 (derivative) @ $0 | EDGAR |
| 2022-12-06 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Option exercise (M): 833 @ $0 · Tax withholding (F): 248 @ $28.83 · Option exercise (M): 833 (derivative) @ $0 | EDGAR |
| 2022-03-03 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Grant/award (A): 11,500 (derivative) @ $0 · Grant/award (A): 41,000 (derivative) @ $0 | EDGAR |
| 2022-02-23 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Option exercise (M): 3,271 @ $0 · Tax withholding (F): 955 @ $29.08 · Option exercise (M): 3,271 (derivative) @ $0 | EDGAR |
| 2022-02-14 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Option exercise (M): 2,162 @ $0 · Tax withholding (F): 758 @ $31.43 · Option exercise (M): 2,162 (derivative) @ $0 | EDGAR |
| 2021-12-07 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Option exercise (M): 834 @ $0 · Tax withholding (F): 248 @ $35 · Option exercise (M): 834 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2021-10-07 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1881190 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs